From: Higher mortality of patients on haemodialysis with pancreatic diabetes compared to type 2-diabetes
 | Pancreatic diabetes | Type 2 diabetes |
---|---|---|
 | (n = 12) | (n = 84) |
Age (years) | 56 ± 6* | 63 ± 8* |
Sex (female %) | 50% | 52% |
Diabetes duration (years) | 17 ± 7 | 18 ± 6 |
HbA1c (%) | 7.5 ± 1.3 | 7.6 ± 1.1 |
Body weight (kg) | 59 ± 7** | 70 ± 11** |
BMI (kg/m2) | 22 ± 3* | 25 ± 4* |
C-peptide basal (ng/ml) | 0.9 ± 0.3* | 1.9 ± 0.6* |
Systolic blood pressure (mm Hg) | 136 ± 12 | 137 ± 10 |
Diastolic blood pressure (mm Hg) | 86 ± 9 | 87 ± 8 |
Antidiabetic therapy (%) | Â | Â |
Diet and sulfonylurea | 0 | 5% |
Conventional insulin therapy | 50% | 44% |
Intensified insulin therapy | 50% | 41% |
Insulin dose (IU/day) | 22+11* | 32+11* |
Vascular access (n/%) | Â | Â |
Arteriovenous fistula | 10 (83%) | 64 (76%) |
Permcath-dialysis catheter | 2 (17/%) | 20 (24%) |
Insulin dose (IU/day) | 22 ± 11* | 32 ± 16* |
Duration of dialysis (hours//week) | 13 (12-15) | 13 (12-15) |
Kt/V (three month after start of HD) | 1.3 | 1.4 |